Aurigene announces manufacturing and supply partnership with global pharma company

Hyderabad-based Aurigene Pharmaceutical Services, a wholly owned subsidiary of Dr. Reddy's Laboratories, has announced a strategic, long-term Manufacturing and Supply Agreement (MSA) with a leading global pharmaceutical company for the commercial drug-product manufacturing and supply of a diversified portfolio for USA, Europe, Canada and Emerging markets.

The agreement establishes a full-service framework for technical transfer, process development, scale-up, validation, commercial manufacturing and long-term supply.

The collaboration highlights Aurigene’s expanding drug product CDMO (Contract Development and Manufacturing Organization) and CMO (Contract Manufacturing Organization) capabilities, particularly in sterile injectables and biologics, complementing its established development and manufacturing expertise across the pharmaceutical value chain.

The initial portfolio comprises 20+ products spanning sterile injectables, biologics and topicals, to be manufactured across facilities in India. The partnership is expected to progress through a phased technology transfer programme over the next two to three years, paving the way for commercial manufacturing and supply.

At full commercialisation, the portfolio is expected to represent an estimated annual volume of approx.18 million units, largely being injectables, with revenues expected to commence from the calendar year 2028.